A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-group Study, which describes the Renal effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the treatment of sub's with Fredrickson Type IIa and Type IIb Dyslipidaemia, inc. Heterozygous Familial Hypercholesterolaemia

Study identifier:D3560C00099

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-group Study, which describes the Renal effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the treatment of sub's with Fredrickson Type IIa and Type IIb Dyslipidaemia, inc. Heterozygous Familial Hypercholesterolaemia

Medical condition

cardiovascular system

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Sept 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria